Dr Jitendra Singh Announces First National Call of ₹2,000 Crore BIRAC–RDI Fund Under ₹1 Lakh Crore RDI Initiative to Boost Biotech Sector

1. At a Glance

• First national call of the ₹2,000 crore BIRAC–RDI Fund, carved out of the ₹1 lakh crore RDI Scheme, announced on 13 Feb 2026 by Dr Jitendra Singh, MoS (IC) Science & Technology [1][2].
• Targets the lab-to-industry gap in biotech; aligns with India's $300 billion bioeconomy target by 2030 and $1 trillion by 2047 [1].
• Important for UPSC across GS-III (S&T, Economy, R&D) and intersects with Anusandhan National Research Foundation (ANRF) governance.

2. Why in the News

• On 13 Feb 2026, BIRAC launched the first call for proposals as a Second-Level Fund Manager (SLFM) under the RDI Scheme [1][2].
• Follows TDB's parallel SLFM call issued on 4 Feb 2026 [2].

3. Background & Evolution

• ANRF Act, 2023 created the Anusandhan National Research Foundation, anchored in the Department of Science & Technology (DST).
• Union Cabinet approved the ₹1 lakh crore RDI Scheme on 1 July 2025 to catalyse private-sector R&D in strategic and sunrise sectors [2].
• ANRF Executive Council later operationalised the Fund and designated TDB and BIRAC as SLFMs [2].
• BIRAC itself was set up in 2012 as a Section 8 PSU under the Department of Biotechnology (DBT).

4. Core Static Facts

• Scheme: Research, Development and Innovation (RDI) Scheme — corpus ₹1,00,000 crore [2].
• BIRAC sub-allocation: ₹2,000 crore to be deployed over up to 5 years [1].
• Apex governance: ANRF Governing Board chaired by the Prime Minister; Executive Council approves guidelines and SLFMs [2].
• Anchor ministry: Department of Science & Technology (RDI Scheme); DBT parents BIRAC [2].
• SLFMs: TDB (call on 4 Feb 2026) and BIRAC (call on 13 Feb 2026) [2].
• India's bioeconomy: USD 28 bn (2012) → USD 165.7 bn (2024); target USD 300 bn by 2030, USD 1 trillion by 2047 [1].
• BIRAC footprint: 100+ bio-incubation centres, >10 lakh sq ft incubation space, engagement with 15 lakh+ startup entrepreneurs [1].

5. Multi-Dimensional Analysis

Economic

• Designed to crowd-in private R&D, where India spends only ~0.65% of GDP on R&D vs. global leaders >2%.
• Bioeconomy scale-up from $165.7 bn to $300 bn in six years implies near-doubling of biotech output [1].

Scientific / Technological

• Funds high-risk, high-impact biotech innovations: biopharma, biomanufacturing, bio-agri, bio-industrial, bio-IT under the BioE3 Policy framework.
• Bridges the "valley of death" between TRL-4 prototypes and commercialisation [1].

Administrative / Governance

• Two-tier architecture: ANRF (apex) → SLFMs (TDB, BIRAC) → end beneficiaries; reduces ministerial bottlenecks [2].
• BIRAC's prior incubator network provides ready last-mile delivery [1].

Strategic

• Reduces import dependence in vaccines, biologics, enzymes; complements Atmanirbhar Bharat in sunrise sectors.
• Positions India as a global bioeconomy hub alongside USA, EU, China.

6. Recent Developments (last 12–18 months)

• 1 Jul 2025: Union Cabinet approves ₹1 lakh crore RDI Scheme [2].
• Nov 2025: RDI Fund operationalised under ANRF [1].
• 4 Feb 2026: TDB issues first SLFM call [2].
• 13 Feb 2026: BIRAC launches ₹2,000 crore first national call [1][2].

7. Prelims Hooks

• RDI Scheme corpus: ₹1,00,000 crore; Cabinet nod on 1 July 2025 [2].
• BIRAC's RDI tranche: ₹2,000 crore over 5 years [1].
• BIRAC is a Section 8 company under the Department of Biotechnology (Ministry of Science & Technology), set up in 2012.
• ANRF established by the Anusandhan National Research Foundation Act, 2023.
• ANRF's Governing Board is chaired by the Prime Minister [2].
• TDB and BIRAC are the Second-Level Fund Managers under the RDI Scheme [2].
• India's bioeconomy in 2024: USD 165.7 billion; target USD 300 bn by 2030 [1].
• Bioeconomy grew from USD 28 bn (2012) — nearly 6× in 12 years [1].
• BIRAC has set up 100+ bio-incubation centres [1].
• Announcement made by Dr Jitendra Singh, MoS (IC) Science & Technology, Earth Sciences; MoS PMO, Personnel [1].
• Anchor ministry for RDI Scheme: DST, not DBT [2].

8. Mains Relevance

• GS-III — Science & Technology: "Developments and their applications and effects in everyday life"; "Indigenization of technology and developing new technology"; "Achievements of Indians in S&T."
• GS-III — Economy: Investment models, growth, employment.
• Sample stems: 1. "Discuss how the ₹1 lakh crore RDI Scheme can address India's structurally low private R&D spending. (250 words)" 2. "India's bioeconomy is poised to be a key driver of the next growth phase. Examine the policy and institutional architecture supporting this transition. (250 words)" 3. "Critically evaluate the two-tier fund management model under ANRF for catalysing private innovation."

9. Related Topics to Study Next

• Anusandhan National Research Foundation (ANRF), 2023 — parent governance body.
• BioE3 Policy (Biotechnology for Economy, Environment & Employment), 2024 — sectoral roadmap.
• Technology Development Board (TDB) — co-SLFM.
• National Quantum Mission & National Deep Tech Startup Policy — sister sunrise initiatives.
• India AI Mission — comparable mission-mode innovation fund.
• Startup India / Fund of Funds for Startups (SIDBI) — financing comparator.
• Genome India Project & Mission COVID Suraksha — flagship DBT-BIRAC programmes.
• Gross Expenditure on R&D (GERD) trends — context metric.

10. Common Errors / Trap Areas

• Ministry confusion: RDI Scheme is anchored in DST, not DBT, even though BIRAC (DBT) is an SLFM [2].
• ANRF ≠ SERB: ANRF subsumed SERB under the 2023 Act.
• Fund-of-Funds nature: RDI provides long-tenure, low-interest loans / equity via SLFMs — not direct grants.
• Chair: ANRF Governing Board is chaired by the PM, not the Minister of S&T [2].
• Bioeconomy figure: USD 165.7 bn (2024) — often misquoted as 2023 or 130 bn.